## SLAB: Silicon Laboratories, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 3.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($126.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Silicon Laboratories' Ascent: Strong Fundamentals Signal Impending RS Rating Boost**
- Source: Markets Financial Content | 20251211T141800 | Bullish | Relevance: 100%
- Silicon Laboratories (NASDAQ: SLAB) is expected to see a significant improvement in its Relative Strength (RS) Rating, driven by strong fundamentals and positive analyst sentiment. The company's focus on low-power wireless IoT chips and AI-capable hardware positions it well within the growing IoT market. This ascent will likely attract more investors, solidifying SLAB's position as a leader in its niche while intensifying competition for rivals.

**2. Silicon Laboratories' Ascent: Strong Fundamentals Signal Impending RS Rating Boost**
- Source: Markets Financial Content | 20251211T141800 | Bullish | Relevance: 100%
- Silicon Laboratories (NASDAQ: SLAB) is poised for a significant upgrade in its Relative Strength (RS) Rating due to strong fundamentals, positive analyst sentiment, and robust stock performance. The company's focus on low-power wireless IoT chips and AI-capable hardware positions it strategically within the burgeoning IoT sector. This ascent has implications for the broader semiconductor market, intensifying competition for rivals while strengthening SLAB's market position, financial buoyancy, and brand image.

**3. Stocks With Rising Relative Strength: Silicon Laboratories**
- Source: Investor's Business Daily | 20251211T130949 | Somewhat-Bullish | Relevance: 100%
- Silicon Laboratories (SLAB) saw its Relative Strength (RS) Rating increase from 64 to 72, though it still falls short of the ideal 80 or higher score investors typically seek. This upgrade indicates an improvement in the stock's price performance compared to other stocks in the market. The exclusive rating from Investor's Business Daily assesses price movement on a scale of 1 to 99, with higher scores being more favorable.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.02M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- FMR, LLC: 15.0% (+0.8%)
- Blackrock Inc.: 13.7% (+2.5%)
- Vanguard Group Inc: 11.8% (+1.9%)
- State Street Corpora: 4.7% (+2.4%)
- Macquarie Group Limi: 3.0% (-8.6%)

### Key Risks

1. Valuation stretched: PEG 3.0x requires aggressive growth execution.
2. Elevated short interest (9.4%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.03 signals overvaluation risk, limited margin of safety. Forward P/E 50.7x attractive for 197% earnings growth. Balance sheet: strong liquidity (4.5x), low leverage (D/E 0.17). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 1.56 |
| 52W Range | $82.82 - $160.00 |
| Short Interest | 9.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.03 |
| Forward P/E | 50.7 |
| Current P/E | 150.6 |
| YoY Growth | 197.1% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 5.2% to 0.1% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.61), confirming momentum. RSI neutral at 55. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.07% (CS: 28) | Neutral |
| RSI_14 | 54.9 | Neutral |
| MACD Histogram | 1.61 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.064x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $136.39
- **Stop Loss:** $126.47 (7.3% risk)
- **Target:** $146.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 100
- **Position Value:** $13,639.00
- **Portfolio %:** 13.64%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-03 (Est: $0.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.32 | +4.2% |
| 2025Q2 | $0.09 | $0.11 | +18.7% |
| 2025Q1 | $-0.09 | $-0.08 | +10.9% |
| 2024Q4 | $-0.11 | $-0.11 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*